Cabozantinib Plus Atezolizumab Significantly Improves PFS in

Combination treatment with cabozantinib and atezolizumab did not produce any new safety signals in the treatment of those with metastatic castration-resistant prostate cancer in the phase 3 CONTACT-02 trial.

Related Keywords

Cabozantinib Cabometyx , Neeraj Agarwal , Vickil Goodman , University Of Utah , Product Development Medical Affairs , Cancer Research At Huntsman Institute , Exelixis Inc , Cancer Network , Cancer Research , Huntsman Cancer Institute , Product Development , Medical Affairs , Prostate Cancer , Prognosis , Cancer , Prostate , Oncology ,